Compare SLE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | APM |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 5.6M |
| IPO Year | 2019 | 2018 |
| Metric | SLE | APM |
|---|---|---|
| Price | $2.75 | $0.70 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | 18.3K | ★ 26.3K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,064,000.00 | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $49.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.48 | $0.60 |
| 52 Week High | $11.43 | $4.47 |
| Indicator | SLE | APM |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 34.93 |
| Support Level | $2.66 | $0.65 |
| Resistance Level | $3.43 | $0.89 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 42.03 | 42.86 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.